Image: Pic: Emil Stach/Ritzau Scanpix/Reuters "We need ... particularly drugmakers like Novo Nordisk, which sells the weight loss drug Wegovy and the type 2 diabetes medicine Ozempic.

There is a long-running health crisis impacting the modern world. According to the World Health Organization, one in eight people worldwide were living with obesity as of 2022. Obesity causes ...

The popularity of Novo Nordisk's Ozempic and Wegovy has attracted competitors and created supply constraints. Novo Nordisk's next-generation weight loss drug disappointed investors in Phase III ...

Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity and diabetes drug, the company announced March 24. The drug ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets, valued at more than $100 billion. Each of them has advantages, as well as dark spots in the pipeline of ...

Well before market open that morning, Morgan Stanley's Thibault Boutherin knocked his Novo Nordisk price target down to 600 Danish kroner ($86.67) per share; previously, this number was 700 kroner ...

Novo Nordisk is expanding discounted sales of its Wegovy weight loss drug. Novo Nordisk is also licensing a new weight loss drug from China. Crunching the data, the news looks relatively worse for ...

The Novo Nordisk Foundation’s project to explore food processing has created some controversy of late. Initially, the project was framed as ‘the next generation’ of the ‘Nova’ classification, with its ...

Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results but remains strong in diabetes treatment, insulin, and GLP-1 products. I outline the bull case ...

Under terms of the license agreement, Novo Nordisk will acquire the rights to develop and commercialize UBT251 outside of China for obesity and type 2 diabetes for an upfront payment of $200 million.

Pharmaceutical giant Novo Nordisk (NYSE: NVO) built its business on insulin and has emerged as a leading innovator in GLP-1 agonists, relatively new drugs that treat obesity and type 2 diabetes by ...